Apogee Therapeutics to report 16-week data from Phase 2 trial of APG777 on July 7.

Apogee Therapeutics, Inc. (Nasdaq: APGE) will report 16-week data from the Phase 2 APEX trial of APG777 on July 7, 2025, for the treatment of various inflammatory and immunology indications. A webcast discussing the results will follow at 8:00 a.m. ET on the same day. Apogee is a biotech company focusing on novel biologics for conditions like atopic dermatitis, asthma, and COPD, aiming to provide better efficacy and dosing. Their most advanced program, APG777, targets atopic dermatitis, with the potential to improve patient outcomes with innovative antibody therapies.

Read more at GlobeNewswire: Apogee Therapeutics to Host Conference Call to Report Part